Literature DB >> 17427022

Subtype and genotypic resistance analysis of HIV-1 infected patients in Austria.

Barbara Falkensammer1, Martin Doerler, Harald H Kessler, Elisabeth Puchhammer-Stoeckl, Walter Parson, Christina Duftner, Manfred P Dierich, Heribert Stoiber.   

Abstract

BACKGROUND: Analysis of HIV-1 subtypes and genotypic resistance have been shown to be relevant for epidemiologic and therapeutic studies or for vaccine development. In Europe, the majority of HIV-1 isolates belong to subtype B. Due to migration an increasing incidence for additional subtypes and complex recombinant forms are expected. OBJECTIVES AND STUDY
DESIGN: To evaluate the prevalence of HIV-1 subtypes in Austria, 188 plasma samples of treatment experienced patients were investigated. For phylogenetic analysis protease and reverse transcriptase genes were amplified and sequenced. Subtypes were determined by comparing reference sequences. For genotypic resistance determination, the Resistance-Algorithm-Comparison from Stanford University was used.
RESULTS: Non-B subtypes were found in 20.2% of all patients with a dominant prevalence (50%) in the Southern provinces of Austria. With 85% CRF01_AE and CRF02_AG are the predominant circulating recombinant forms in Austria. When resistance mutations were analyzed, 57.4% of all patients were susceptible to all three groups of antiretroviral drugs, whereas in 12.2% resistance against all three classes of antiretroviral drugs was found.
CONCLUSION: HIV-1 subtype B is still dominant in major parts of Austria. However, a significantly increasing percentage of non-B subtypes and recombinant forms are observed in the Southern provinces.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17427022     DOI: 10.1007/s00508-006-0745-4

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  26 in total

1.  HIV-1 LTR subtype and perinatal transmission.

Authors:  J T Blackard; B Renjifo; W Fawzi; E Hertzmark; G Msamanga; D Mwakagile; D Hunter; D Spiegelman; N Sharghi; C Kagoma; M Essex
Journal:  Virology       Date:  2001-09-01       Impact factor: 3.616

2.  Antiretroviral therapy of HIV infection. German-Austrian recommendations (July 2002).

Authors: 
Journal:  Eur J Med Res       Date:  2003-06-30       Impact factor: 2.175

3.  Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.

Authors:  H Walter; B Schmidt; K Korn; A M Vandamme; T Harrer; K Uberla
Journal:  J Clin Virol       Date:  1999-06       Impact factor: 3.168

4.  Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.

Authors:  L Vergne; M Peeters; E Mpoudi-Ngole; A Bourgeois; F Liegeois; C Toure-Kane; S Mboup; C Mulanga-Kabeya; E Saman; J Jourdan; J Reynes; E Delaporte
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

5.  Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests.

Authors:  L L Jagodzinski; D L Wiggins; J L McManis; S Emery; J Overbaugh; M Robb; S Bodrug; N L Michael
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

6.  Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function.

Authors:  M A Montano; C P Nixon; T Ndung'u; H Bussmann; V A Novitsky; D Dickman; M Essex
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

Review 7.  Genotypic testing for human immunodeficiency virus type 1 drug resistance.

Authors:  Robert W Shafer
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

8.  Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms.

Authors:  Rute Antunes; Sofia Figueiredo; Inês Bártolo; Manuel Pinheiro; Lino Rosado; Isabel Soares; Helena Lourenço; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains.

Authors:  E Puchhammer-Stöckl; C Steininger; E Geringer; F X Heinz
Journal:  HIV Med       Date:  2002-07       Impact factor: 3.180

10.  HIV type 1 diversity in northeastern Romania in 200-2001 based on phylogenic analysis of pol sequences from patient failing antiretroviral therapy.

Authors:  Cristian Apetrei; Diane Descamps; Gilles Collin; David L Robertson; Ivona Pandrea; Petru Groza; Liviu Prisecariu; Irina Teodorescu; Vasile Luca; Françoise Brun-Vézinet
Journal:  AIDS Res Hum Retroviruses       Date:  2003-12       Impact factor: 2.205

View more
  2 in total

1.  Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy.

Authors:  Nazle Mendonca Collaço Véras; Maria Mercedes Santoro; Rebecca R Gray; Andrew J Tatem; Alessandra Lo Presti; Flaminia Olearo; Giulia Cappelli; Vittorio Colizzi; Desiré Takou; Judith Torimiro; Gianluca Russo; Annapaola Callegaro; Romina Salpini; Roberta D'Arrigo; Carlo-Federico Perno; Maureen M Goodenow; Massimo Ciccozzi; Marco Salemi
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-06       Impact factor: 2.205

2.  Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Tagliamonte; Francesca Vitone; Maria Carla Re; Elisabetta Pilotti; Claudio Casoli; Costanza Sbreglia; Oreste Perrella; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Infect Agent Cancer       Date:  2008-10-10       Impact factor: 2.965

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.